• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

New technologies in clinical trials – do we truly saving the costs?

11.04.2017/in News /by daryab

Clinical trials are still somewhat behind the general trend when it comes to embracing new technologies. A survey conducted by the Clinical Data Interchange Standards Consortium

(CDISC) and CenterWatch of 750 members throughout the clinical research community suggests that 75% of trials still rely on paper data collection as their primary tool. This is in spite of the fact that electronic data collection tools have been available for more than 20 years.

These kinds of inefficiencies are costing the industry big.

According to CDISC and CenterWatch survey respondents, the current set of available options simply aren’t up to par. 69% of sponsors and 67% of CROs feel that existing technological applications do not have “adequate functionality to meet the current needs.” As a result, the rate of tech innovation and adoption has stagnated, and efficiency has been on the steady decline.

It seems like respondents were just not informed about novel available options, unfortunately.

Many sponsors utilize online screeners and call centers to reduce some of the recruitment burden on the site level. However, when this information is siloed, patients are often subjected to the same questions or processes when they arrive at the investigator site.

Interestingly, recent surveys show that up to 50% of patients considering participating in a clinical trial listed lack of transportation as a barrier. AbbVie, Merck, Sage Therapeutics, Ironwood, and Acadia partnered with with mobile car service provider Lyft to offer transportation to patients enrolled in clinical trials.

Coping with extraneous data is also a key strategy for conserving money. According to research from Tufts CSDD, losses due to avoidable data-related issues range between $4 and $6 billion each year. The problem is widespread, the report explains, affecting roughly one in five (22.3%) trials for more than $1 million per trial. A greater percentage of Phase III trials collected extraneous data (24.7) than Phase II trials (17.7%) did.

Medical Device Innovation Consortium (MDIC) offers a solution. Proposed strategy differs substantially from the common practice of leveraging a prior study protocol and making modifications in response to current stakeholder requests. MDIC offers to reduce points in clinical research forms (CRFs) and carefully watch database development and management.

Data inefficiencies-related financial burden is well-recognized for a long time. Earlier in 2009 a ban for patient paper diaries in favor of electronic was proposed to achieve cost reductions. Back in 2014 electronic CRFs were estimated to be roughly three times cheaper than paper CRFs.

Relentless pharma market growth should not be a reason to ignore implementation of cost-effective strategies into clinical research. And since all the market participants are willing to reduce expenses, we will eventually face the inevitable future.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 0 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Our decisive “No” to unproven interventions – British Medical Journal... The scientific and practical conference “Expertise and Registration of...
Scroll to top